HC Wainwright Rates Gossamer Bio (GOSS) buy, $2 Price Target
HC Wainwright maintains a buy rating on Gossamer Bio, Inc. with a $2.00 price target, a 1173.89% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated Gossamer Bio, Inc. ($GOSS) "buy" with a $2 price target on June 25, 2026.
Since the rating, $GOSS is up 4.8% after 1 week, up 20.6% after 1 month and down 33.6% to date (from the $13.20 close on Jun 25, 2026).
GOSS
Gossamer Bio, Inc.
Key Points
- HC Wainwright reiterated its buy rating for Gossamer Bio, Inc. (GOSS) with a $2.00 price target as of June 25, 2026.
- HC Wainwright's $2 price target implies 1173.89% upside from Gossamer Bio, Inc.'s ($GOSS) current $0.16 share price.
- Shares of Gossamer Bio traded near $0.17 on Friday, with a market cap of $80.7 million and a beta of 2.005.
- Gossamer Bio insiders made significant purchases, while institutional investors like AQR Capital Management increased their stakes.
Get $GOSS trade alerts by text
We text you when insiders, Congress or big funds trade $GOSS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Gossamer Bio, Inc. alert may contain errors. Disclosures
On June 25, 2026, HC Wainwright reiterated its buy rating for Gossamer Bio, Inc. (NasdaqGS: GOSS), setting a price target of $2.00. Analyst Patrick R. Trucchio maintained this optimistic outlook, highlighting the potential growth prospects for the biotechnology company.
HC Wainwright & Co. vs. the S&P 500
Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Gossamer Bio, Inc.
BlackRock, Inc. slightly trimmed its holdings by 230,183 shares, bringing its total to 16,826,695 shares valued at approximately $5.53 million, a 1.3% decrease. Kalehua Capital Management LLC initiated a new position with 10,236,293 shares worth about $3.36 million. AQR Capital Management LLC significantly boosted its stake by 9,007,657 shares, now holding 10,126,897 shares valued at $3.33 million, marking an 804.8% increase. Vanguard Capital Management LLC also opened a new position, acquiring 9,394,593 shares valued at $3.09 million. Meanwhile, Octagon Capital Advisors LP reduced its stake by 6,165,371 shares, now holding 7,750,000 shares worth approximately $2.55 million, a 44.3% decrease.
Gossamer Bio, Inc. Stock Down 98.5%
Shares of Gossamer Bio, Inc. traded near $0.17 on Friday. The company has a market cap of about $80.7 million and a beta of 2.005, indicating higher volatility compared to the market. Over the past 52 weeks, the stock has ranged from $0.14 to $3.87. Its 50-day moving average stands at $0.27, while the 200-day moving average is $1.72. Gossamer Bio maintains a current ratio of 2.204 and a quick ratio of 1.921, reflecting its ability to meet short-term obligations.
$GOSS price target
Gossamer Bio, Inc. daily closes and this analyst's $2 target. Not advice.
Recent Earnings
Gossamer Bio reported revenue of $55.54 million, with a notable growth rate of 71.5%. Despite this growth, the company reported a net margin of 0.0%, indicating it is not yet profitable. The next earnings report is anticipated on August 5, 2026.
Insider Buying and Selling at Gossamer Bio, Inc.
On June 4, 2026, several insiders, including Daniel Thomas, John Quisel, Steven Nathan, Russell Cox, Skye Drynan, and Sandra Milligan, each acquired 115,000 shares of Gossamer Bio. These transactions were not part of any pre-planned trading program.
Analysts Set New Price Targets
On June 25, 2026, HC Wainwright & Co. maintained its buy rating on Gossamer Bio, Inc. with a price target of $2.00. Earlier, on May 19, 2026, Barclays maintained a sell rating and set a lower target of $0.28. The consensus among analysts is a buy recommendation, with a mean target price of $3.86 based on five analyst opinions.
About Gossamer Bio, Inc.
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. Led by CEO Faheem Hasnain, the company focuses on developing treatments for pulmonary diseases, including pulmonary hypertension. Its lead product candidate, seralutinib, is in Phase 3 trials. With approximately 161 employees, Gossamer Bio aims to address unmet medical needs in the healthcare sector.
Bottom Line
HC Wainwright's reiterated buy rating on Gossamer Bio, Inc. reflects confidence in the company's future potential, despite its current financial challenges. Investors closely watch such analyst ratings as they provide insights into a company's prospects. It's important to remember that these ratings are based on past filings and may not reflect the current market conditions.
Related Filing Alerts
Source: HC Wainwright's rating change on $GOSS (Jun 25, 2026). Written by software, not financial advice. How we make alerts